cas 51019-43-3|| where to buy (R)-2-Acetoxy-2-phenylacetic acid

Nom du produit:(R)-2-Acetoxy-2-phenylacetic acid

IUPAC Name:(2R)-2-(acetyloxy)-2-phenylacetic acid

Unité d'emballage	Stock disponible	Prix($)	Quantité
CM253292-500g	in stock	ǎǟĳ

Pour une utilisation en R&D uniquement..

Formulaire de demande

Nom chimique

Numéro CAS

Quantité*

Spécifications requises*
(% d'analyse, qualité du matériau, etc.)

Nom du contact*

Email du contact*

Meanwhile I'd like to create a registered account on CHEMENU.COM with the above email.

I'd like to receive emails related to products with similar structures to 51019-43-3 regularly via the above email.

Notes supplémentaires

Verification code*

refresh

: N° CAS:51019-43-3; Formule moléculaire:C10H10O4; Point de fusion:-; Code SMILES:O=C(O)[C@H](OC(C)=O)C1=CC=CC=C1; Densité:

: Numéro de catalogue:CM253292; Poids moléculaire:194.19; Point d'ébullition:317.8°C at 760 mmHg; N° Mdl:MFCD00004249; Stockage:Store at room temperature.

: Benzenes; Benzene is an important organic compound with the chemical formula C6H6, and its molecule consists of a ring of 6 carbon atoms, each with 1 hydrogen atom. Benzene is a sweet, flammable, colorless and transparent liquid with carcinogenic toxicity at room temperature, and has a strong aromatic odor. It is insoluble in water, easily soluble in organic solvents, and can also be used as an organic solvent itself. The ring system of benzene is called benzene ring, and the structure after removing one hydrogen atom from the benzene ring is called phenyl. Benzene is one of the most important basic organic chemical raw materials. Many important chemical intermediates can be derived from benzene through substitution reaction, addition reaction and benzene ring cleavage reaction.

: Samuraciclib; Carrick Therapeutics’ Phase 2 Clinical Trial of Samuraciclib combined with Fulvestrant has dosed its first patient. The study targets patients with CDK4/6i resistant HR+, HER2- metastatic breast cancer. Samuraciclib is a selective oral, first-in-class inhibitor of CDK7. It is involved in the regulation of cancer-causing genes, promotion of uncontrolled cell cycle progression, and increase in resistance to anti-hormone therapy. The comb previously receives the Fast Track Designation from the U.S. FDA.